[Polyglandular autoimmune syndromes]

Area of Science:

• Endocrinology
• Immunology
• Genetics

Context:

• Polyglandular autoimmune diseases (PAGD) represent a group of rare disorders.
• Characterized by the simultaneous or sequential occurrence of autoimmune conditions affecting multiple endocrine glands.
• PAGD are classified into types I, II, and III, each with distinct clinical and genetic features.

Purpose:

• To review the current understanding of the pathophysiology, clinical manifestations, and genetic basis of polyglandular autoimmune diseases.
• To highlight the diagnostic challenges and management strategies for these complex conditions.
• To emphasize the importance of early diagnosis and comprehensive screening for associated autoimmune disorders.

Summary:

• PAGD are defined by the presence of two or more organ-specific autoimmune disorders.
• Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) or type I PAGD is caused by mutations in the AIRE gene.
• Type II PAGD (Schmidt syndrome) is associated with HLA-DR3 and HLA-DR4 haplotypes and involves autoimmune thyroid disease and type 1 diabetes.
• Type III PAGD is characterized by autoimmune thyroid disease and other autoimmune conditions, excluding type 1 diabetes and Addison's disease.

Impact:

• Understanding the genetic and immunological underpinnings of PAGD is crucial for developing targeted therapies.
• Improved diagnostic criteria and screening protocols can lead to earlier detection and better management of PAGD.
• Raising awareness among healthcare professionals about the potential for multiple autoimmune conditions in affected individuals can improve patient outcomes.